Source: CureToday articles
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial’s primary end point for those with myelofibrosis.
Recent Content
- NLA: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
- Novel Agents, Promising Data: The Evolving Landscape of Oncology Care
- Day 1: Top Takeaways From ASCO25
- NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome
- Rapid Developments to Enhance Patient Experience in GU Cancer
- Proactive Dermatologic Care Reduces Symptom Severity and Boosts Quality of Life in NSCLC
- ASCO 2025: Racial Disparities and Advanced Staging in Early-Onset Colorectal Cancer
- Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes
- FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease
- The Healing Power of Teddy Bears for Adults With Cancer